Cargando…

HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs

Multiple myeloma (MM), a malignant plasma cell infiltration of the bone marrow, is generally considered incurable: resistance to multiple therapeutic drugs inevitably arises from tumor cell-intrinsic and tumor microenvironment (TME)-mediated mechanisms. Here we report that the proteoglycan tandem re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huynh, Mailee, Chang, Hae Yeun, Lisiero, Dominique N., Ong, Irene M., Kashyap, Trinayan, Callander, Natalie S., Miyamoto, Shigeki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045543/ https://www.ncbi.nlm.nih.gov/pubmed/36480501 http://dx.doi.org/10.1371/journal.pone.0274704

Ejemplares similares

HAPLN1 matrikine: a bone marrow homing factor linked to poor outcomes in patients with MM
por: Chang, Hae Yeun, et al.
Publicado: (2023)

Ectopic CH60 mediates HAPLN1-induced cell survival signaling in multiple myeloma
por: De Bakshi, Debayan, et al.
Publicado: (2022)

Hapln2 in Neurological Diseases and Its Potential as Therapeutic Target
por: Wang, Qinqin, et al.
Publicado: (2019)

HAPLN1 potentiates peritoneal metastasis in pancreatic cancer
por: Wiedmann, Lena, et al.
Publicado: (2023)

Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells
por: Markovina, Stephanie, et al.
Publicado: (2010)

Metformin, an AMPK Activator, Inhibits Activation of FLSs but Promotes HAPLN1 Secretion
por: Chen, Yong, et al.
Publicado: (2020)

Novel Effect of Hyaluronan and Proteoglycan Link Protein 1 (HAPLN1) on Hair Follicle Cells Proliferation and Hair Growth
por: Ha, Hae Chan, et al.
Publicado: (2023)

hapln1a(+) cells guide coronary growth during heart morphogenesis and regeneration
por: Sun, Jisheng, et al.
Publicado: (2023)

A Novel Role of Hyaluronic Acid and Proteoglycan Link Protein 1 (HAPLN1) in Delaying Vascular Endothelial Cell Senescence
por: Zhou, Dan, et al.
Publicado: (2023)

Hapln1a Is Required for Connexin43-Dependent Growth and Patterning in the Regenerating Fin Skeleton
por: Govindan, Jayalakshmi, et al.
Publicado: (2014)

Elevated Hapln2 Expression Contributes to Protein Aggregation and Neurodegeneration in an Animal Model of Parkinson's Disease
por: Wang, Qinqin, et al.
Publicado: (2016)

HAPLN1 Affects Cell Viability and Promotes the Pro-Inflammatory Phenotype of Fibroblast-Like Synoviocytes
por: Chen, Yong, et al.
Publicado: (2022)

A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation
por: Cass, Michael, et al.
Publicado: (2022)

Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death
por: Argueta, Christian, et al.
Publicado: (2018)

Acetyl-l-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network
por: Callander, Natalie, et al.
Publicado: (2014)

Asymmetric Hapln1a drives regionalized cardiac ECM expansion and promotes heart morphogenesis in zebrafish development
por: Derrick, Christopher J, et al.
Publicado: (2021)

Hapln1b, a central organizer of the ECM, modulates kit signaling to control developmental hematopoiesis in zebrafish
por: Mahony, Christopher B., et al.
Publicado: (2021)

Abnormal expression of chondroitin sulphate N-acetylgalactosaminyltransferase 1 and Hapln-1 in cartilage with Kashin–Beck disease and primary osteoarthritis
por: Zheng, Jingjing, et al.
Publicado: (2013)

Cancer-associated fibroblasts-derived HAPLN1 promotes tumour invasion through extracellular matrix remodeling in gastric cancer
por: Zhang, Tiancheng, et al.
Publicado: (2021)

Transcriptome Analysis Reveals MFGE8-HAPLN3 Fusion as a Novel Biomarker in Triple-Negative Breast Cancer
por: Wang, Meng-Yuan, et al.
Publicado: (2021)

ASPN Synergizes with HAPLN1 to Inhibit the Osteogenic Differentiation of Bone Marrow Mesenchymal Stromal Cells and Extracellular Matrix Mineralization of Osteoblasts
por: Zhou, Guohui, et al.
Publicado: (2023)

Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy
por: Longcor, Jarrod, et al.
Publicado: (2022)

De novo HAPLN1 expression hallmarks Wnt-induced stem cell and fibrogenic networks leading to aggressive human hepatocellular carcinomas
por: Mebarki, Sihem, et al.
Publicado: (2016)

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
por: Turner, Joel G., et al.
Publicado: (2016)

Role and Therapeutic Targeting of SDF-1α/CXCR4 Axis in Multiple Myeloma
por: Ito, Shigeki, et al.
Publicado: (2021)

Cx43-Dependent Skeletal Phenotypes Are Mediated by Interactions between the Hapln1a-ECM and Sema3d during Fin Regeneration
por: Govindan, Jayalakshmi, et al.
Publicado: (2016)

Recombinant Human HAPLN1 Mitigates Pulmonary Emphysema by Increasing TGF-β Receptor I and Sirtuins Levels in Human Alveolar Epithelial Cells
por: Piao, Yongwei, et al.
Publicado: (2023)

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
por: Kumar, Shaji, et al.
Publicado: (2022)

Proteasome Inhibitors for the Treatment of Multiple Myeloma
por: Ito, Shigeki
Publicado: (2020)

Role of β4 integrin phosphorylation in human invasive squamous cell carcinoma: regulation of hemidesmosome stability modulates cell migration
por: Kashyap, Trinayan, et al.
Publicado: (2011)

Therapeutic Advancements in Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2014)

The Association of HLA Class 1 and Class 2 Antigens with Multiple Myeloma in Iranian Patients
por: Sayad, Arezou, et al.
Publicado: (2014)

MiR-19b alleviates MPP(+)-induced neuronal cytotoxicity via targeting the HAPLN4/MAPK pathway in SH-SY5Y cells
por: Liu, Wei, et al.
Publicado: (2018)

Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges
por: Sklavenitis-Pistofidis, Romanos, et al.
Publicado: (2022)

The LIN28B/let-7 axis is a novel therapeutic pathway in Multiple Myeloma
por: Manier, Salomon, et al.
Publicado: (2016)

P807: CLASS Ⅱ FERROPTOSIS INDUCERS ARE A NOVEL THERAPEUTIC APPROACH FOR T(4;14)-POSITIVE MULTIPLE MYELOMA
por: Zhang, Jiasi, et al.
Publicado: (2023)

Persistence with Antihypertensive Medications in Uncomplicated Treatment-Naïve Patients: Effects of Initial Therapeutic Classes
por: Ah, Young-Mi, et al.
Publicado: (2015)

P843: METABOLOMIC CHARACTERIZATION OF HUMAN MULTIPLE MYELOMA CELL LINE TO STUDY TUMOR RESISTANCE TO DIFFERENT CLASSES OF THERAPEUTIC AGENTS
por: Steer, A., et al.
Publicado: (2022)

Evolving therapeutic role of bisphosphonates in multiple myeloma
por: Ural, A U, et al.
Publicado: (2005)

MMSET: Role and Therapeutic Opportunities in Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_aeq08emqb56ovt6f0asgbkel0c